Cargando…
Bright future or blind alley? CAR-T cell therapy for solid tumors
Chimeric antigen receptor (CAR) T cells therapy has emerged as a significant breakthrough in adoptive immunotherapy for hematological malignancies with FDA approval. However, the application of CAR-T cell therapy in solid tumors remains challenging, mostly due to lack of suitable CAR-T target antige...
Autores principales: | Zhang, Kai, Chen, Hong, Li, Fuqiang, Huang, Sheng, Chen, Fei, Li, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902507/ https://www.ncbi.nlm.nih.gov/pubmed/36761757 http://dx.doi.org/10.3389/fimmu.2023.1045024 |
Ejemplares similares
-
Clinical Investigations of CAR-T Cell Therapy for Solid Tumors
por: Chen, Kun, et al.
Publicado: (2022) -
Stem Cell Therapy for the Heart: Blind Alley or Magic Bullet?
por: Bruyneel, Arne A. N., et al.
Publicado: (2016) -
Blind-Alley Hospital Employments: The Case of the Laboratory Boy
Publicado: (1913) -
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
por: Knochelmann, Hannah M., et al.
Publicado: (2018) -
Combining chemotherapy with CAR-T cell therapy in treating solid tumors
por: Wang, Arthur Xuan, et al.
Publicado: (2023)